Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138868 | 0.73 | NPSR1 (0.55) | ALDH1A1NPC1POLBHTTRAB9A | |
| SCHEMBL4732141 | 0.72 | NPSR1 (0.44) | ALDH1A1NPC1POLBHTTRAB9A | |
| SCHEMBL10596450 | 0.71 | NPSR1 (0.53) | ALDH1A1NPC1POLBHTTRAB9A | |
| SCHEMBL1769746 | 0.71 | NPSR1 (0.53) | ALDH1A1NPC1POLBHTTRAB9A | |
| SCHEMBL8521295 | 0.71 | CRHBP (0.42) | ALDH1A1NPC1POLBHTTRAB9A | |
| SCHEMBL155509 | 0.70 | ALOX5 (0.44) | ALDH1A1NPC1POLBHTTRAB9A | |
| SCHEMBL12475197 | 0.70 | ALDH1A1 (0.61) | ALDH1A1KMT2ANPSR1TP53SMN1; SMN2 | |
| SCHEMBL3244381 | 0.69 | KMT2A (0.46) | ALDH1A1NPC1POLBHTTKMT2A | |
| SCHEMBL6871207 | 0.68 | ALDH1A1 (0.50) | ALDH1A1POLBKMT2ATP53SMN1; SMN2 | |
| SCHEMBL28575888 | 0.67 | NPSR1 (0.57) | ALDH1A1NPC1POLBHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3808743-B1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-20 | — | — | EP | disclosed |
| EP-3808743-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | Janssen Pharmaceutica NV (BE) | 2021-04-21 | — | — | EP | disclosed |
| US-10611732-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-07 | — | — | US | disclosed |
| EP-2298761-B1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-25 | — | — | EP | disclosed |
| US-20190322628-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-24 | — | — | US | disclosed |
| US-10370340-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-06 | — | — | US | disclosed |
| US-20180244632-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-30 | — | — | US | disclosed |
| US-9981919-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICAL N.V. (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20170320835-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-20170121292-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-04 | — | — | US | disclosed |
| EP-1567134-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A BASIC RESPECTIVELY ACIDIC DRUG COMPOUND, A SURFACTANT AND A PHYSIOLOGICALLY TOLERABLE WATER-SOLUBLE ACID RESPECTIVELY BASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1529032-A1 | PROCESSES FOR THE PREPARATION OF 4- 4- 4-(2 -CYANOETHENYL)-2,6-DIMETHYLPHENYL )AMINO) -2-PYRIMIDINYL)AMINO BENZONITRILE | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040198739-A1 | Prevention reproduction of virus | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-10-07 | — | — | US | disclosed |
| WO-2004074261-A1 | HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074262-A1 | HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004050068-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A BASIC RESPECTIVELY ACIDIC DRUG COMPOUND, A SURFACTANT AND A PHYSIOLOGICALLY TOLERABLE WATER-SOLUBLE ACID RESPECTIVELY BASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050058-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A BASIC RESPECTIVELY ACIDIC DRUG COMPOUND, A SURFACTANT AND A PHYSIOLOGICALLY TOLERABLE WATER-SOLUBLE ACID RESPECTIVELY BASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-17 | — | — | WO | disclosed |
| EP-1419152-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-19 | — | — | EP | disclosed |
| WO-2004016581-A1 | PROCESSES FOR THE PREPARATION OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BENZONITRILE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-26 | — | — | WO | disclosed |
| WO-2003016306-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121292-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | ALDH1A1 3445/4885NPC1 636/4885POLB 50/4885 |
| US-20190322628-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | ALDH1A1 3445/4885NPC1 636/4885POLB 50/4885 |
| US-10611732-B2 | HIV replication inhibiting pyrimidines | RRM2B, CCNO, RRM2 | ALDH1A1 3445/4885NPC1 636/4885POLB 50/4885 |
| US-20180244632-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | ALDH1A1 3445/4885NPC1 636/4885POLB 50/4885 |
| US-20040198739-A1 | Prevention reproduction of virus | ZC3HAV1, HAVCR2, CBR1 | ALDH1A1 2007/4885NPC1 121/4885POLB 215/4885 |
| US-10370340-B2 | HIV replication inhibiting pyrimidines | RRM2B, CCNO, RRM2 | ALDH1A1 3445/4885NPC1 636/4885POLB 50/4885 |
| US-20170320835-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | ALDH1A1 3445/4885NPC1 636/4885POLB 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.